Interleukin 6 and complement serum level study in Parkinson's
disease

J 2018

Interleukin 6 and complement serum level study in Parkinson's disease

VESELÝ, Branislav, Michal DUFEK, Vojtěch THON, M. BROZMAN, S. KIRALOVA et. al.

Basic information

Original name

Interleukin 6 and complement serum level study in Parkinson's disease

Authors

VESELÝ, Branislav (703 Slovakia, belonging to the institution), Michal DUFEK (203 Czech Republic, belonging to the institution), Vojtěch THON (203 Czech Republic, belonging to the institution), M. BROZMAN (703 Slovakia), S. KIRALOVA (703 Slovakia), T. HALASZOVA (703 Slovakia), Eva KORIŤÁKOVÁ (203 Czech Republic, belonging to the institution) and Ivan REKTOR (203 Czech Republic, guarantor, belonging to the institution)

Edition

Journal of Neural Transmission, WIEN, SPRINGER WIEN, 2018, 0300-9564

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30103 Neurosciences

Country of publisher

Austria

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.903

RIV identification code

RIV/00216224:14740/18:00103549

Organization unit

Central European Institute of Technology

DOI

http://dx.doi.org/10.1007/s00702-018-1857-5

UT WoS

000430583400010

Keywords in English

Complement; Interleukin 6; Parkinson's disease

Abstract

V originále

The objective of this study is to assess whether elevation of serum inflammatory markers levels may indicate the progression of clinical impairment in Parkinson's disease (PD) patients. In 47 PD patients, the serum levels of the C3 and C4 part of the complement and Interleukin-6 (IL-6) were measured. The results at baseline and after 2 years were correlated with scales measuring memory, depression, motor symptoms, and quality of life. Patients with higher levels of C3 and C4 at baseline had decreased quality of life, verbal ability, and memory. Patients with higher IL-6 at baseline showed worse depression scores at 2 years. Patients with persistently higher levels of C3 and C4 at 2 years had worse quality of life and memory ability. Uncorrected p values are reported due to the exploratory nature of the study. The results indicate an impact of inflammation on non-motor signs and quality of life in PD. The increase of levels of serum inflammatory biomarkers may indicate the progression of non-motor impairment in PD.

Links

LQ1601, research and development project

Name: CEITEC 2020 (Acronym: CEITEC2020)

Investor: Ministry of Education, Youth and Sports of the CR

Citovat

VESELÝ, Branislav, Michal DUFEK, Vojtěch THON, M. BROZMAN, S. KIRALOVA, T. HALASZOVA, Eva KORIŤÁKOVÁ and Ivan REKTOR. Interleukin 6 and complement serum level study in Parkinson's disease. Journal of Neural Transmission. WIEN: SPRINGER WIEN, 2018, vol. 125, No 5, p. 875-881. ISSN 0300-9564. Available from: https://dx.doi.org/10.1007/s00702-018-1857-5.

@article{1431177,
   author = {Veselý, Branislav and Dufek, Michal and Thon, Vojtěch and Brozman, M. and Kiralova, S. and Halaszova, T. and Koriťáková, Eva and Rektor, Ivan},
   article_location = {WIEN},
   article_number = {5},
   doi = {http://dx.doi.org/10.1007/s00702-018-1857-5},
   keywords = {Complement; Interleukin 6; Parkinson's disease},
   language = {eng},
   issn = {0300-9564},
   journal = {Journal of Neural Transmission},
   title = {Interleukin 6 and complement serum level study in Parkinson's disease},
   url = {https://link.springer.com/article/10.1007%2Fs00702-018-1857-5},
   volume = {125},
   year = {2018}
}

TY  - JOUR
ID  - 1431177
AU  - Veselý, Branislav - Dufek, Michal - Thon, Vojtěch - Brozman, M. - Kiralova, S. - Halaszova, T. - Koriťáková, Eva - Rektor, Ivan
PY  - 2018
TI  - Interleukin 6 and complement serum level study in Parkinson's disease
JF  - Journal of Neural Transmission
VL  - 125
IS  - 5
SP  - 875-881
EP  - 875-881
PB  - SPRINGER WIEN
SN  - 03009564
KW  - Complement
KW  - Interleukin 6
KW  - Parkinson's disease
UR  - https://link.springer.com/article/10.1007%2Fs00702-018-1857-5
L2  - https://link.springer.com/article/10.1007%2Fs00702-018-1857-5
N2  - The objective of this study is to assess whether elevation of serum inflammatory markers levels may indicate the progression of clinical impairment in Parkinson's disease (PD) patients. In 47 PD patients, the serum levels of the C3 and C4 part of the complement and Interleukin-6 (IL-6) were measured. The results at baseline and after 2 years were correlated with scales measuring memory, depression, motor symptoms, and quality of life. Patients with higher levels of C3 and C4 at baseline had decreased quality of life, verbal ability, and memory. Patients with higher IL-6 at baseline showed worse depression scores at 2 years. Patients with persistently higher levels of C3 and C4 at 2 years had worse quality of life and memory ability. Uncorrected p values are reported due to the exploratory nature of the study. The results indicate an impact of inflammation on non-motor signs and quality of life in PD. The increase of levels of serum inflammatory biomarkers may indicate the progression of non-motor impairment in PD.
ER  -

VESELÝ, Branislav, Michal DUFEK, Vojtěch THON, M. BROZMAN, S. KIRALOVA, T. HALASZOVA, Eva KORIŤÁKOVÁ and Ivan REKTOR. Interleukin 6 and complement serum level study in Parkinson's disease. \textit{Journal of Neural Transmission}. WIEN: SPRINGER WIEN, 2018, vol.~125, No~5, p.~875-881. ISSN~0300-9564. Available from: https://dx.doi.org/10.1007/s00702-018-1857-5.

Detailed Information on Publication Record